MX2011006400A - Metodos y composiciones basadas en circovirus porcino tipo 2 (pcv2) para el tratamiento de cerdos. - Google Patents

Metodos y composiciones basadas en circovirus porcino tipo 2 (pcv2) para el tratamiento de cerdos.

Info

Publication number
MX2011006400A
MX2011006400A MX2011006400A MX2011006400A MX2011006400A MX 2011006400 A MX2011006400 A MX 2011006400A MX 2011006400 A MX2011006400 A MX 2011006400A MX 2011006400 A MX2011006400 A MX 2011006400A MX 2011006400 A MX2011006400 A MX 2011006400A
Authority
MX
Mexico
Prior art keywords
compositions
pcv
pigs
treatment
based methods
Prior art date
Application number
MX2011006400A
Other languages
English (en)
Inventor
Michael G Sheppard
Sui T Lay
Original Assignee
Vectogen Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectogen Pty Ltd filed Critical Vectogen Pty Ltd
Publication of MX2011006400A publication Critical patent/MX2011006400A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para vacunar cerdos contra enfermedades asociadas con circovirus porcino tipo 2 (PCV2). En particular, la invención se refiere a vectores de expresión recombinante que permite la secreción o la expresión de membrana celular de una forma truncada de la proteína del cuadro 2 de lectura abierta (ORF2) de PCV2.
MX2011006400A 2008-12-15 2009-12-14 Metodos y composiciones basadas en circovirus porcino tipo 2 (pcv2) para el tratamiento de cerdos. MX2011006400A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12255508P 2008-12-15 2008-12-15
PCT/AU2009/001616 WO2010068969A1 (en) 2008-12-15 2009-12-14 Pcv 2-based methods and compositions for the treatment of pigs

Publications (1)

Publication Number Publication Date
MX2011006400A true MX2011006400A (es) 2011-09-15

Family

ID=42240826

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006400A MX2011006400A (es) 2008-12-15 2009-12-14 Metodos y composiciones basadas en circovirus porcino tipo 2 (pcv2) para el tratamiento de cerdos.

Country Status (14)

Country Link
US (1) US20100150959A1 (es)
EP (1) EP2376639A1 (es)
JP (1) JP2012511896A (es)
KR (1) KR20110123725A (es)
CN (1) CN102333876A (es)
AR (1) AR074678A1 (es)
AU (1) AU2009328622A1 (es)
BR (1) BRPI0923514A2 (es)
CA (1) CA2746340A1 (es)
EA (1) EA201170813A1 (es)
MX (1) MX2011006400A (es)
SG (1) SG172183A1 (es)
TW (1) TW201026850A (es)
WO (1) WO2010068969A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
DK3127551T3 (da) 2005-12-29 2020-10-12 Boehringer Ingelheim Animal Health Usa Inc Pcv2-immunogen-sammensætning til at mindske kliniske symptomer i grise
EP1968630B1 (en) 2005-12-29 2018-01-24 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions
US20100129397A1 (en) 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CN101884787A (zh) * 2010-07-22 2010-11-17 洛阳普莱柯生物工程有限公司 猪圆环病毒2型亚单位疫苗及其制备方法
CN102827289B (zh) * 2012-08-30 2014-04-09 青岛蔚蓝生物股份有限公司 猪圆环病毒2型Cap蛋白和胸腺素α1融合蛋白及应用
CN102824634B (zh) * 2012-09-14 2014-03-19 范红结 表达猪圆环病毒2型Cap蛋白的重组猪痘病毒载体疫苗及其制备方法
CN103920146A (zh) * 2013-01-14 2014-07-16 普莱柯生物工程股份有限公司 猪圆环病毒ⅱ型与猪伪狂犬病二联疫苗及其制备方法和应用
EP2789346A1 (en) 2013-04-11 2014-10-15 CEVA Santé Animale SA Fusion polypeptides and vaccines
WO2014187822A1 (en) * 2013-05-22 2014-11-27 Boehringer Ingelheim Espana, S.A. Method for the reduction of pcv-2 in a herd of swine
CN104031925A (zh) * 2014-02-24 2014-09-10 福州大北农生物技术有限公司 优化的猪圆环病毒orf2基因的nls序列
CN104017813A (zh) * 2014-06-03 2014-09-03 斯澳生物科技（苏州）有限公司 截短的pcv2型衣壳蛋白orf2病毒样颗粒及其制备方法
US10767185B2 (en) * 2015-12-28 2020-09-08 Agricultural Technology Research Institute Method of preparing porcine circovirus type 2 capsid protein and pharmaceutical composition comprising same
EP3254692A1 (en) 2016-06-10 2017-12-13 Ceva Sante Animale Multivalent recombinant spv
CN106399350B (zh) * 2016-09-07 2020-02-21 复旦大学 一种猪圆环病毒ii型病毒样颗粒疫苗及其制备方法
HUE064720T2 (hu) 2017-10-17 2024-04-28 Intervet Int Bv PCV2B ORF2 protein rekombináns expressziója rovarsejtekben
GB2574609A (en) * 2018-06-11 2019-12-18 Univ Cape Town Plant produced porcine circovirus pseudovirion
PE20211141A1 (es) * 2019-12-19 2021-06-25 Farm Veterinarios S A C Salmonella enteritidis recombinante y su uso como vacuna porcina
CN112834744A (zh) * 2020-12-31 2021-05-25 天津瑞普生物技术股份有限公司 一种猪群体内腺病毒3型中和抗体阳性率的elisa试剂盒及其检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831023A (en) * 1982-11-01 1998-11-03 Genentech, Inc. Recombinant animal interferon polypeptides
US5151267A (en) * 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
AUPO856097A0 (en) * 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
FR2789695B1 (fr) * 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
US6852705B2 (en) * 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
CN1769434A (zh) * 2005-08-30 2006-05-10 广东省农业科学院兽医研究所 一种猪圆环病毒2型重组腺病毒及其构建方法和应用
BRPI0714932A2 (pt) * 2006-07-28 2013-05-21 Commw Scient Ind Res Org mÉtodos e composiÇÕes para aumento do tropismo tecidual de vetores adenovirais recombinantes
CN101092631B (zh) * 2007-05-31 2010-04-14 华中农业大学 一种修饰的猪圆环病毒2型orf2基因及应用

Also Published As

Publication number Publication date
BRPI0923514A2 (pt) 2019-08-20
CN102333876A (zh) 2012-01-25
WO2010068969A1 (en) 2010-06-24
AU2009328622A1 (en) 2011-07-07
AR074678A1 (es) 2011-02-02
EA201170813A1 (ru) 2012-01-30
US20100150959A1 (en) 2010-06-17
KR20110123725A (ko) 2011-11-15
EP2376639A1 (en) 2011-10-19
TW201026850A (en) 2010-07-16
JP2012511896A (ja) 2012-05-31
SG172183A1 (en) 2011-07-28
CA2746340A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
MX2011006400A (es) Metodos y composiciones basadas en circovirus porcino tipo 2 (pcv2) para el tratamiento de cerdos.
GB0712160D0 (en) Methods and compositions in the treatment of procine circoviral infection
PH12014502525A1 (en) Multivalent pcv2 immunogenic compositions and methods of producing such compositions
MY152149A (en) Prevention and treatment of sub-clinical pcvd
UA100502C2 (ru) Лечение prdc с применением антигена pcv2
MY171300A (en) Pharmaceutical composition
MX2009010492A (es) Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
IN2012DN00338A (es)
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
MX2012011543A (es) Tratamiento de sarcoidosis empleando celulas madre placentarias.
NZ593474A (en) Compositions and methods for treatment of celiac disease
WO2011017440A3 (en) Implanting organ ports
MY151051A (en) Vaccination against dengue virus infection
UA95458C2 (ru) Вакцина против pcv-2 у mda-положительных поросят
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
ES2622087T3 (es) Vacuna recombinante contra paramyxovirus aviar y procedimiento de fabricación y utilización de la misma
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
AR063606A1 (es) Estabilizacion de vacunas mediante liofilizacion
MY166537A (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
MX352641B (es) Vacuna contra pcv2 basada en peptidos de diseño.
WO2009152147A3 (en) Compositions and methods for dengue virus (dv) treatment and vaccination
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
MD4481B1 (ro) Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV
UA114286C2 (uk) Спосіб лікування staphylococcus aureus

Legal Events

Date Code Title Description
FA Abandonment or withdrawal